The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Open accessAbstract
Cytotoxic chemotherapy remains the mainstay of treatment for triple-negative breast cancer (TNBC) despite the promise of new targeted and biologic agents. Many studies have shown significant benefit of chemotherapy in the neoadjuvant, adjuvant, and metastatic treatment of TNBC. Neoadjuvant chemotherapy studies have consistently reported higher response rates in TNBC than non-TNBC, and pathologic complete response has been shown to predict improved long-term outcomes for TNBC. Although the specific adjuvant regimens that may be most effective for TNBC are still being determined, third-generation chemotherapy regimens using dose dense or metronomic polychemotherapy are among the most effective tools presently available. The role of specific chemotherapy agents in the treatment of TNBC remains incompletely defined and warrants careful review to ensure that the most effective therapy is delivered while minimizing unnecessary toxicity. Platinum agents have seen renewed interest in TNBC based on a growing body of preclinical and clinical data suggesting encouraging activity. Taxanes and anthracyclines are active in TNBC and remain important agents but have not shown specific benefit over non-TNBC. Capecitabine has limited reported data in TNBC, but some reports suggest differential activity in TNBC compared with hormone receptor-positive breast cancer. TNBC is itself a heterogeneous group in which subgroups such as BRCA1 mutation carriers may have particular sensitivity to platinum agents and relatively less sensitivity to taxanes. Therefore, the identification of additional molecular biomarkers to predict response to specific chemotherapy is required to further improve treatment strategies with the current menu of chemotherapy options and future combinations with targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Mamounas, E. P., Bryant, J., Lembersky, B., Fehrenbacher, L., Sedlacek, S. M., Fisher, B., Wickerham, D. L., Yothers, G., Soran, A., & Wolmark, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.517 · Cited by 714
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Guarneri, V., Broglio, K., Kau, S.-W., Cristofanilli, M., Buzdar, A. U., Valero, V., Buchholz, T., Meric, F., Middleton, L., Hortobagyi, G. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6914 · Cited by 601
Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R., & Bishop, D. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000276200 · Cited by 583
Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Muss, H. B., Berry, D. A., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., Dressler, L. G., Cohen, H. J., Becker, H. P., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810266 · Cited by 554
Hugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Kassam, F., Enright, K., Dent, R., Dranitsaris, G., Myers, J., Flynn, C., Fralick, M., Kumar, R., & Clemons, M. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.005 · Cited by 474
von Minckwitz, G., Raab, G., Caputo, A., Schütte, M., Hilfrich, J., Blohmer, J. U., Gerber, B., Costa, S. D., Merkle, E., Eidtmann, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.078 · Cited by 417
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.
Quinn, J. E., Kennedy, R. D., Mullan, P. B., Gilmore, P. M., Carty, M., Johnston, P. G., & Harkin, D. P. (2003) · PubMed · Cited by 400
Moynahan, M. E., Cui, T. Y., & Jasin, M. (2001) · PubMed · Cited by 382
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M. L., Goel, A., Barbieri, V, Costanzo, F., Boland, C. R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600859 · Cited by 361
Colleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0380 · Cited by 353
What is triple-negative breast cancer?
Irvin, W. J., & Carey, L. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.034 · Cited by 350
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
Husain, A., He, G., Venkatraman, E. S., & Spriggs, D. R. (1998) · PubMed · Cited by 291
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2008) · The Lancet · doi:10.1016/s0140-6736(08)60069-0 · Cited by 279
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
Ring, A. E., Smith, I. E., Ashley, S., Fulford, L. G., & Lakhani, S. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602235 · Cited by 262
Cisplatin as first-line therapy for metastatic breast cancer.
Sledge, G. W., Loehrer, P. J., Roth, B. J., & Einhorn, L. H. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1811 · Cited by 225
Platinum-based chemotherapy in triple-negative breast cancer
Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220
211 BRCA1 functions as a differential modulator of chemotherapy induced apoptosis
Quinn, J. E., Kennedy, R. D., Mullan, P. B., Johnston, P. G., & Harkin, D. P. (2004) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(04)80219-2 · Cited by 215
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Lafarge, S., Sylvain, V., Ferrara, M., & Bignon, Y.-J. (2001) · Oncogene · doi:10.1038/sj.onc.1204812 · Cited by 187
Keam, B., Im, S., Kim, H.-J., Oh, D., Kim, J. H., Lee, S., Chie, E. K., Han, W., Kim, D.-W., Moon, W. K., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-203 · Cited by 157
Harris, L. N., Broadwater, G., Lin, N., Miron, A., Schnitt, S. J., Cowan, D., Lara, J. F., Bleiweiss, I. J., Berry, D. A., Ellis, M. J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1622 · Cited by 154
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer: Table 1
Chappuis, P. O., Goffin, J., Wong, N., Perret, C., Ghadirian, P., Tonin, P. N., & Foulkes, W. D. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.608 · Cited by 147
Rodríguez-Pinilla, S. M., Honrado, E., Hardisson, D., Benitez, J. J., & Palacios, J. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9184-1 · Cited by 135
Darb‐Esfahani, S., Loibl, S., Müller, B. M., Roller, M., Denkert, C., Komor, M., Schlüns, K., Blohmer, J., Budczies, J., Gerber, B., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2363 · Cited by 118
Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R. E., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H. H., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm551 · Cited by 103
Frasci, G., Comella, P., Rinaldo, M., Iodice, G., Bonito, M. D., D’Aiuto, M., Petrillo, A., Lastoria, S., Siani, C., Comella, G., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn748 · Cited by 90
Torrisi, R., Balduzzi, A., Ghisini, R., Rocca, A., Bottiglieri, L., Giovanardi, F., Veronesi, P., Luini, A., Orlando, L., Viale, G., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0652-z · Cited by 89
Mazouni, C., Kau, S., Frye, D., André, F., Kuerer, H. M., Buchholz, T. A., Symmans, W. F., Anderson, K., Hess, K. R., Gonzalez-Angulo, A. M., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm008 · Cited by 74
Uhm, J. E., Park, Y. H., Yi, S. Y., Cho, E. Y., Choi, Y., Lee, S. J., Park, M. J., Lee, S., Jun, H. J., Ahn, J. S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24090 · Cited by 72
Psychosocial aspects of cancer genetics: Women at high risk for breast and ovarian cancer
Kash, K. M., Ortega-Verdejo, K., Dabney, M. K., Holland, J. C., Miller, D. G., & Osborne, M. P. (2000) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(200006)18:4<287::aid-ssu3>3.0.co;2-5 · Cited by 50
Ostrow, S. S., Egorin, M. J., Aisner, J., Bachur, N. R., & Wiernik, P. H. (1980) · PubMed · Cited by 49
Wysocki, P. J., Korski, K., Lamperska, K. M., Załuski, J., & Mackiewicz, A. A. (2008) · PubMed · Cited by 48
Ezzat, A. A., Ibrahim, E. M., Ajarim, D. S., Rahal, M. M., Raja, M. A., Tulbah, A. M., Almalik, O., Alshabanah, M., & Sörbris, R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601616 · Cited by 44
‘Triple Negative’ Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials
Kilburn, L. S. (2008) · Clinical Oncology · doi:10.1016/j.clon.2007.09.010 · Cited by 37
Response from the Cochrane Collaboration
Clarke, M. J., Tharyan, P., & Green, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60196-8 · Cited by 24
Cited by
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
DNA Methyltransferases: A Novel Target for Prevention and Therapy
Subramaniam, D., Thombre, R., Dhar, A., & Anant, S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00080 · Cited by 476
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Self-citationDelayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
Chavez-MacGregor, M., Clarke, C. A., Lichtensztajn, D. Y., & Giordano, S. H. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3856 · Cited by 370
Metadata
- Authors
- Isakoff, S. J.
- Venue
- The Cancer Journal
- Published
- 2010-01
- Volume
- 16
- Issue
- 1
- Pages
- 53-61
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W2068868056
- Cited by
- 348
- References
- 55
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.